Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Giuseppe Cuccia, Giuseppe Privitera, Federica Di Vincenzo, Lucia Monastero, Laura Parisio, Luigi Carbone, Franco Scaldaferri, Daniela Pugliese

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Personalised medicine and the identification of predictors of the efficacy of specific drugs represent the ultimate goal for the treatment of ulcerative colitis (UC) in order to break the current therapeutic ceiling. JAK inhibitors are a new class of advanced therapies, orally administered, showing a good profile of efficacy and safety in both randomised controlled trials (RCTs) and real-world studies. Unfortunately, to date, it is not possible to draw the ideal profile of a patient maximally benefiting from this class of drugs to guide clinicians' therapeutic choices. Baseline clinical activities and inflammatory biomarkers, as well as their early variation after treatment initiation, emerged as the main predictors of efficacy from post hoc analyses of RCTs with tofacitinib. Similar findings were also observed in the real-life studies including mainly patients with a history of pluri-refractoriness to biological therapies. At last, a few new biomarkers have been explored, even though they have not been validated in large cohorts. This paper provides a review of the current knowledge on clinical variables and biomarkers predicting response to JAK inhibitors in UC.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJournal of Clinical Medicine
Volume13
DOI
Stato di pubblicazionePubblicato - 2024

Keywords

  • JAK inhibitors
  • biomarkers
  • predictors
  • ulcerative colitis

Fingerprint

Entra nei temi di ricerca di 'Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis'. Insieme formano una fingerprint unica.

Cita questo